GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Genmab A/S GMAB.CO · DKK

Health Care · Nasdaq Copenhagen · 🇩🇰 Denmark

Compare

3,661.00

+3.80%

Close of 9 Nov 2026, in DKK

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Genmab A/S — daily GMAB

No embeddable chart for this listing. TradingView's free widgets do not cover this exchange, and an unsupported symbol would render an error panel rather than a chart.

View Genmab A/S on TradingView ↗
Market value
DKK 229.51bn
Last close × shares
Volume
140.5k
Shares, 9 Nov 2026
Price to earnings
227.3

About Genmab A/S

Its shares trade on Nasdaq Copenhagen under the ticker GMAB.CO. It has been listed since 1 October 2000. In the fiscal year to 31 December 2025, it reported revenue of $592.6m and net income of $153.4m. At that date it held total assets of $1.97bn and shareholders' equity of $895.7m.

Genmab A/S operates as an international biotechnology company. The company specializes in the creation and development of antibody therapeutics for the treatment of cancer. The firm is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Figures and description from our data supplier, not checked against the company's own report.

More about Genmab A/S →

Latest on Genmab A/S

Our reporting

Next results

5 Nov 2026

Due on 5 Nov 2026. Analysts expect earnings of 23.26 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Genmab A/S's ticker?

Genmab A/S trades as GMAB.CO on Nasdaq Copenhagen, under ISIN DK0010272202.

What was Genmab A/S's last closing price?

3,661.00 on 9 Nov 2026. The figure is in DKK and is never converted.

When does Genmab A/S next report results?

Results are expected on 5 Nov 2026, according to our data supplier.

Sources and methodology

Chart
TradingView
Close and company data
Our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.